Horizon 2020
Work Programme
for Research & Innovation
2018-2020

The societal challenge
'Health, demographic change
and well-being'

Opportunities for SMEs

Laszlo Helmle, Policy Officer
Health Directorate
DG Research and Innovation
European Commission
Health Research in Horizon 2020

- Collaborative R&I projects
- Grants for small businesses
- InnovFin: Loans for small & large companies
- Public-Private Partnership with big Pharma
- Horizon Prize
- Education - R&D - Innovation
- Blue sky research
- Public-Public Partnerships with EU Member States & beyond
- Innovative Medicines Initiative (IMI)
- AAL Programme
- JPND Research
- Eurostars
- SME Instrument
- Fast Track to Innovation
EU definition of Small and Medium-sized Enterprise (SME)$^1$

Any autonomous entity engaged in an economic activity, irrespective of its legal form, with the following characteristics:

- $< 250$ employees
- $\leq \varepsilon 50$ million annual turnover, *and/or*
- $\leq \varepsilon 43$ million annual balance sheet

$^1$ COMMISSION RECOMMENDATION of 6 May 2003 concerning the definition of micro, small and medium-sized enterprises (2003/361/EC)
European Innovation Council: pilot 2018-2020
€ 2.7 billion to support +5,000 SMEs and innovators

ECOSYSTEM SUPPORT: **COACHING, MENTORING** for all SME beneficiaries

**FET-OPEN**
Future Emerging Technologies

**FTI**
Fast Track to Innovation

**SME Instrument**
Phase 1

**SME Instrument**
Phase 2

**6 EIC HORIZON PRIZES:**

1. Innovative Batteries for eVehicles
2. Fuel from the Sun: Artificial Photosynthesis
3. Early Warning for Epidemics
4. Blockchains for Social Good
5. Low-Cost Space Launch
6. Affordable-HighTech for Humanitarian Aid
Submission of proposals

Remote Evaluation

Ranking of Proposals

Interview

Invitation to GAP

• Fully bottom-up approach with the removal of topics as defined in the previous Work Programmes

• Revised weighting of the award criteria - 50% for Impact, 25% for Excellence and 25% Quality of implementation.

• Revised threshold – 13/15 for the overall final score and 4/5 at criteria level

• Starting with the highest-scoring proposal and in descending order, proposals are passed to the Interview stage until, either the total amount of EU funding requested is as close as possible to twice the budget available, or all proposals eligible for funding have been accounted for

• Face-to-Face Interview in Brussels

• Interview process composed of two steps – Jury interview and Panel Review

• Proposals above all thresholds in remote evaluation and receiving an A mark in the interview with be invited to GAP
SME Instrument Phase 2 – interviews

- All interviews take place in Brussels
- All interviews take place during one week per cut-off dates
  - Interview weeks: 12-16 Feb; 16-20 Apr; 25-29 Jun; 12-16 Nov
  - Applicants are requested to ensure availability during that week when applying
- A maximum of three company representatives per proposal
  - Representation by third parties is forbidden (i.e. no consultants)
  - Presence of senior company officers is recommended
- Applicants must prepare a pitch deck and send it in advance
## European Innovation Council pilot

<table>
<thead>
<tr>
<th>Instrument →</th>
<th>SME-Instrument</th>
<th>FTI</th>
<th>FET-Open</th>
<th>EIC Horizon prizes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Phase 1</td>
<td>Phase 2</td>
<td>From 3 to 5 eligible entities (mostly industrial)</td>
<td>At least 3 entities</td>
</tr>
<tr>
<td><strong>For whom</strong></td>
<td>One or more eligible SMEs</td>
<td>From 3 to 5 eligible entities (mostly industrial)</td>
<td>At least 3 entities</td>
<td>One or more entities (with restrictions for some of the prizes)</td>
</tr>
<tr>
<td><strong>Maximum funding</strong></td>
<td>50,000 €</td>
<td>2.5 M€</td>
<td>3 M€</td>
<td>3 M€ (RIAs) 0.5 M€ (CSAs)</td>
</tr>
<tr>
<td><strong>Total budget 2018-20</strong></td>
<td>164 M€</td>
<td>1,425 M€</td>
<td>300 M€</td>
<td>647 M€ (RIAs) 10 M€ (CSAs)</td>
</tr>
<tr>
<td><strong>Focus</strong></td>
<td>Exploring the feasibility of a business idea (~ 6 months)</td>
<td>Breakthrough innovation &amp; international growth (12-24 months)</td>
<td>Close-to-market innovation</td>
<td>Radically new technologies</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6 different topics (major societal issues)</td>
</tr>
</tbody>
</table>

(1) Applicants must be established in an EU Member State or in a country associated to Horizon 2020
(2) This industry involvement implies: (a) either the allocation of at least 60% of the budget to industry participants in the consortium, or (b) the presence of a minimum number of two industry participants in a consortium of three or four partners, or of three industry participants in a consortium of five partners
(3) A FET-Open consortium must always include at least 3 participants from 3 different EU Member States or Associated Countries. In addition to these three partners, any legal entity from anywhere in the world can also be included in the consortium.
(4) Per project – with possible exceptions
Eurostars under Horizon 2020

1.148 billion
Eurostars total public budget 2014-2020

75% + 25%
EUROSTARS COUNTRIES CONTRIBUTION + EU CONTRIBUTION
Eligibility

Project leader is an R&D-performing SME from a Eurostars country

At least 2 Participants
- Autonomous entities
- Legal entities from at least 2 Eurostars countries

SMEs are in the driving seat
International balance

Project duration is max. 3 years
Market introduction within 2 years
## InnovFin - EU Finance for Innovators

<table>
<thead>
<tr>
<th>SMEs</th>
<th>Midcaps</th>
<th>Large Caps</th>
<th>Thematic Finance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>InnovFin</strong> SME Guarantee</td>
<td><strong>InnovFin</strong> MidCap Guarantee</td>
<td><strong>InnovFin</strong> Large Projects</td>
<td><strong>InnovFin</strong> Energy Demo Projects</td>
</tr>
<tr>
<td><strong>InnovFin</strong> SME Venture Capital</td>
<td><strong>InnovFin</strong> MidCap Growth Finance</td>
<td></td>
<td><strong>InnovFin</strong> Infectious Diseases</td>
</tr>
</tbody>
</table>

- SMEs and small Mid-Caps < 500 Employees
- Intermediated SME/Mid-Cap Financing
- Mid-Caps < 3,000 Employees
- Intermediated and/or direct Corporate lending
- Large Caps Typically > 3,000 Employees
- Direct Corporate Lending
- SPV, Mid-Caps and Large Caps
- Project Finance and/or Direct Corporate Lending
Financial Instrument for Infectious Diseases R&D

- Jointly developed by EC and EIB
- Provides loans between EUR 7.5m and EUR 75m
- No calls: demand-driven
- Must be in pre-commercial phase with proof-of-concept and pre-clinical research phases completed and clinical validation required for further development.
- Must have proven public health impact and potentially have market prospects.
- Should provide for the intellectual property created in the course of the project to remain in the EU
More information and support is available for:

• Call text, guide for applicants, FAQ: **Participant portal**

• Horizon 2020 **Work Programmes**

• Practical information & local assistance: **National Contact Points**

• IP questions and advice: **IPR helpdesk**
  [https://www.iprhelpdesk.eu/](https://www.iprhelpdesk.eu/)

• **Eurostars**
  [https://www.eurostars-eureka.eu/](https://www.eurostars-eureka.eu/)

• **InnovFin** Infectious Diseases Finance Facility: EIB

• Loan guarantee, equity: **financial support available in your country**

International partnership, business innovation: **Enterprise Europe Network**
Any questions?

@EUScienceInnov
#InvestEUresearch
#EUHealthResearch

http://ec.europa.eu/research/health
http://ec.europa.eu/research/participants/portal